All Updates

All Updates

icon
Filter
Funding
En Carta Diagnostics raises EUR 1.5 million in pre-seed funding to advance Lyme disease testing kits
Precision Medicine
May 27, 2024
This week:
Robinhood launches joint investment accounts
Retail Trading Infrastructure
Jul 25, 2024
Partnerships
eToro partners with London Stock Exchange to expand UK stock offerings
Retail Trading Infrastructure
Jul 25, 2024
Funding
StorMagic secures funding from Palatine Growth Credit Fund
Edge Computing
Jul 25, 2024
Funding
Archera raises USD 17 million in Series B funding for product development and recruitment
Cloud Optimization Tools
Jul 25, 2024
Funding
Alto Neuroscience receives grant of USD 11.7 million to support Phase IIb clinical trials of ALTO-100
Precision Medicine
Jul 25, 2024
Partnerships
Quest Diagnostics and BD partner to develop flow cytometry-based companion diagnostics for cancer and other diseases
Precision Medicine
Jul 25, 2024
Product updates
USPACE Technology Group Limited unveils commercial optical satellites and related aerospace products
Next-gen Satellites
Jul 25, 2024
Industry news
Sweden issues study on Gripen fighter jet’s satellite launch capability
Next-gen Satellites
Jul 25, 2024
Product updates
Regulation/policy
Terran Orbital receives certification for new manufacturing facility to begin production
Next-gen Satellites
Jul 25, 2024
Partnerships
Crisalion Mobility partners with Air Chateau for pre-order of eVTOL aircraft
Passenger eVTOL Aircraft
Jul 25, 2024
Precision Medicine

Precision Medicine

May 27, 2024

En Carta Diagnostics raises EUR 1.5 million in pre-seed funding to advance Lyme disease testing kits

Funding

  • Point-of-care molecular diagnostics startup En Carta Diagnostics has raised EUR 1.5 million (USD 1.63 million) in a pre-seed funding round led by CentraleSupélec Venture, with participation from several other investors.

  • The raised funds will be channeled toward achieving preclinical data on a diagnostic kit prototype for chronic Lyme disease. The company also plans to use the funds to establish a robust ecosystem and enhance its market entry strategies.

  • Based in France, En Carta Diagnostics is a biotechnology company that develops point-of-care (POC) molecular diagnostics for various pathogens kits using synthetic biology. The company’s main therapeutic focus area is chronic Lyme disease. En Carta’s technology facilitates the creation of diagnostic kits that can be used without specialized equipment or training.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.